etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users
News provided by
Share this article
Share this article
GAINESVILLE, Fla. & BOSTON, May 4, 2021 /PRNewswire/ Digital health company, etectRx, Inc., today announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV. The study, dubbed MyTPill, will assess patient adherence using two electronic adherence tracking technologies: the ID-Cap
™ System from etectRx and an electronic pill box. The study will provide insight on how digital pill systems can help patients who have significant health risks due to nonadherence.
The MyTPill Study, which marks etectRx s third NIH-sponsored study at Brigham and Women s Hospital within the last two years, kicked off in March, and will include 80 patients over the next four years. Patients will track their use of HIV medication by using the ID-Cap System for three month
etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BB lv: А сухие фрукты – лучше!
bb.lv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bb.lv Daily Mail and Mail on Sunday newspapers.
Are Digital Pills in Your Future?
New pills raise privacy and ethical concerns over their ability to send a signal to up to 5 people when taken
In November 2017, the FDA approved the digital pill Abilify MyCite to treat schizophrenia, depression, and bipolar disorder(1); a one-month supply costs $1,500, well out of range of affordability for many suffering from schizophrenia(2).
The pill includes a digital sensor that reacts with stomach acid when taken, sending a signal to a patch worn by the patient that then sends a signal to a smartphone app notifying up to five people that the pill was taken.
Share
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma. we are going to quarterly, and we are going to talk about the market: Hey, what is pharma doing out there in clinical trials? Combing clinicaltrials.gov and approach them, and say could a combined solution like ours advance our clinical trials?” Valerie Sullivan, CEO of etectRx told